Nektar Therapeutics NKTR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
/UPDATE — Nektar Therapeutics/
-
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
-
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
-
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update
-
Nektar Gets $90 Million Jury Award in Breach Suit Vs Eli Lilly
-
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Trading Information
- Previous Close Price
- $60.55
- Day Range
- $46.29–56.69
- 52-Week Range
- $33.40–109.00
- Bid/Ask
- $47.10 / $47.49
- Shares Outstanding
- 34.14M
- Market Cap
- $1.60B
- Volume/Avg
- 6M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 63
- Website
- https://www.nektar.com
Valuation
|
Metric
|
NKTR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.78 |
Price/Sales | 20.92 |
Price/Cash Flow | — |
Price/Earnings
NKTR
Financial Strength
|
Metric
|
NKTR
|
|---|---|
Quick Ratio | 9.71 |
Current Ratio | 10.42 |
Interest Coverage | −4.56 |
Quick Ratio
NKTR
Profitability
|
Metric
|
NKTR
|
|---|---|
Return on Assets (Normalized) | −26.38% |
Return on Equity (Normalized) | −42.85% |
Return on Invested Capital (Normalized) | −31.56% |
Return on Assets
NKTR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#c<>?^ | LOCK|@%&?& | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|z%cSvJ< | LOCK|tdCb> | $76B | |||
| Moderna Inc
MRNA
| LOCK|Kj!C^<# | LOCK|N? | $75B | |||
| argenx SE ADR
ARGX
| LOCK|<D!VJMN | LOCK|kf | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Z<M><! | LOCK|$K% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|x&$z&D | LOCK|tY^j | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<>r<^@$ | LOCK|F@h? | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Rcmf?p | LOCK|d$$ | $24B | |||
| Incyte Corp
INCY
| LOCK|%%%<?!^ | LOCK|#m | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|n<cpD<> | LOCK|DB | $15B |
United States